Leerink analyst downgrades Bristol Myers over pipeline concerns

A Leerink analyst signaled new bearishness on Bristol Myers Squibb, downgrading the company's stock rating.

Analyst David Risinger moved the rating from outperform to a lower stance, saying he is skeptical about several upcoming catalysts.

The downgrade centers on doubts surrounding three advanced programs in Bristol Myers' pipeline, though the report does not name the specific drugs.

Risinger's assessment adds to broader concerns among investors about the company's near‑term growth prospects.